HTN Flashcards

1
Q

What percentage of HTN is PRIMARY

A

90-95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What percentage of HTN is SECONDARY?

A

5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Think secondary HTN if

A

▪ If sudden onset, esp. if age of onset < 20 or > 50 years
▪ BP > 180/100
▪ Resistance to therapy
▪ Pt with well-controlled HTN has sudden increase in BP
▪ There are symptoms that could cause secondary HTN: headache, daytime
somnolence, fatigue, tachycardia, claudication, cold feet, sweating, thinning of
skin, flank pain, muscle weakness, tremor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HTN Diagnosis

A

Average of readings taken at 2 or more visits

• Must have 2 separate elevated readings

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe steps in Renin Angiotensin System (RAS)

A

Drop in BP to renal arteries stimulates secretion of renin
• Renin activates renin-angiotensin system, yields angiotensin I
• Angiotensin converting enzyme (ACE) converts angiotensin I converted to angiotensin II
• Angiotensin II constricts blood cells, increases secretion of antidiuretic hormone (ADH) and
aldosterone, causes reabsorption of Na+ in kidneys –> water retention, increased blood volume,
increased BP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Factors that affect BP

A

Peripheral vascular resistance
• Body position
• Activity
• Blood volume
• Obesity – leads to increased intravascular volume and increased cardiac output
• Lifestyle
• Environmental factors
• Alcohol – increases BP by increasing plasma catecholamines
• Cigarettes – raises BP by increasing plasma norepinephinre
• NSAIDs – cause fluid retention, which can lead to HTN
• Excessive intake of Na+ or low levels of K+ - can contribute to HTN by increasing blood volume
Downloaded by

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HTN is a major risk factor for…

A
Cardiovascular dz
o Ischemic heart dz
o Heart attack
o Heart failure
• Stroke
• Kidney dz, renal failure
• Peripheral vascular dz
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Each increase of 20 mm Hg in SBP or 10 mm Hg in DBP

A

DOUBLES risk of cardiovascular dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Initial drug therapy for Prehypertension 120-139 or 80-89

A

none

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Initial drug therapy for Stage 1 HTN 140-159 or 90-99

A

Thiazide diuretic
-may consider ACE,
ARB, BB, CCB, or
combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Initial drug therapy for Stage 2 HTN ≥160 or ≥100

A

Two-drug combo
(usually thiazide + ACE,
ARB, BB, or CCB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Centrally acting α-2 agonists (antiadrenergics) MOA

A

Stimulate central inhibitory α-adrenergic receptors
• Stimulate sympathetic cardioaccelerator and vasoconstrictor areas
• Results in decreased sympathetic outflow from CNS that causes reduced peripheral resistance,
renal vascular resistance, decreased HR, decreased BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clonidine:

A

• Onset of action: 30-60 min
• Duration of action: 6-10 hr
• Metabolism: extensive hepatic
• Excretion: kidney 65%, feces 22%
• Drug interactions:
▪ Tricyclic antidepressants decease effects of clonidine
▪ Clonidine may enhance CNS effects of alcohol or sedatives
▪ Use cautiously with β-blockers. Clonidine can cause bradycardia. Discontinue gradually.
• Side effects:
▪ Dry mouth, drowsiness, dizziness, sedation, orthostatic hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Methyldopa

A
Onset of action: 3-6 hr
• Duration of action: 12-24 hr
• Metabolism: complex liver
• Excretion: kidney 70% drug and conjugates
• Drug interactions:
▪ Lithium
▪ MAOIs
▪ Iron salts
▪ COMT inhibitors
• Pregnancy: preferred HTN drug in pregnancy
• Side effects:
▪ Headache, asthenia, dizziness, gynecomastia, GI distress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are the characteristics of systolic dysfunction?

A

reduced left ventricular , low ejection fraction

EF usually less than 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the characteristics of diastolic dysfunction?

A

Characterized by “stiffening” of the left ventricle
EF is typically preserved,
i.e. normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is preload?

A

Stretch of the ventricle prior to contraction. Preload is
created by blood filling the ventricle in preparation for
contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is afterload?

A

Resistance the left ventricle has to overcome to empty its

contents into peripheral circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is peripheral vascular resistance?

A

Pressure (within the periphery) that the left ventricle

must overcome with each contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the New York Heart Association (NYHA)

HF Classification I-IV?

A

 I –asymptomatic or only symptomatic with activities that
would limit anyone

 II– symptomatic with usual exertion

 III– symptomatic with minimal exertion

 IV—symptomatic at rest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are Non-Pharmacologic Management of HF?

A

Sodium restriction
 Smoking cessation when applicable
 Limited alcohol intake (one drink per day in women or 2 drinks per day in men)
 Daily aerobic exercise
 Lipid control
 Glucose control in diabetics
 Tight BP control
 Avoid NSAIDS due to potential of increased fluid
retention
 Treatment of thyroid conditions when applicable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How do Loop diuretics treat HF?

A

Work in the ascending loop of Henle to inhibit sodium
and potassium reabsorption

Causes decreased renal blood flow resulting in less fluid
being absorbed back into the bloodstream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How do ACE Inhibitors work to control HF?

A

Produce vasodilation by inhibiting the conversion of
angiotensin I to angiotensin II
 Inhibit the breakdown of bradykinin which is a
powerful vasodilator
 Reduce CV preload
 Reduce CV afterload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How do ARBs work to treat HF?

A

Blocks angiotensin II (a powerful vasoconstrictor) on the
surface of target cells
 Angiotensin receptors noted as AT1 or AT2
 Does not interfere with bradykinin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How do Beta blockers work to treat HF?

A
 Blockade of beta adrenergic receptors resulting in: 
 Decreased heart rate 
 Decreased BP 
 Decreased oxygen demand  
 Promote peripheral vasodilation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How does Spironolactone work to treat HF?

A

Works in the distal renal tubule
 Aldosterone antagonist
 Sodium and water are excreted
 Potassium is retained

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How does Digoxin work to treat HF?

A

Inhibits NA+/K+ pump+
 Increases myocardial contractility
 Decreases heart rate

 Very long half-life: 36 hours
 5-6 days to reach steady state
 Requires loading dose
 Narrow therapeutic window

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is some Patient Teaching for HF ?

A

 Medication compliance

 Patient participation in treatment plan

 Daily weights

 Healthy diet

 Fluid restriction when applicable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Name the drug classes for HTN - ABCD

A

ACE Inhibitors (angiotensin-converting enzyme inhibitors)
ARBs (Angiotensin II Receptor Blockers)
Alpha blockers

Beta Blockers

Calcium Channel Blockers

Diuretics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

which class of HTN meds end in ‘pril’

A

ACE inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

which class or HTN meds end in ‘sartan’

A

ARBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

which class or HTN meds end in ‘osin’ or ‘zosin’?

A

alpha blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

which class or HTN meds end in ‘lol’ ?

A

Beta Blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

which class or HTN meds end in ‘dipine’?

A

calcium channel blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

which class or HTN meds end in ‘ide’?

A

diuretics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is the indication for Beta Blockers?

A

systolic and diastolic failure, but esp. If diastolic HF is caused by increased diastolic filling time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the MOA for Beta Blockers?

A

Blockade of beta adrenergic receptors resulting in:

  • Decreased HR
  • Decreased BP
  • Decreased O2 demand
  • Increase diastolic filling time
  • Peripheral vasodilation
  • Regression of L-ventricular hypertrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What are the precautions for Beta blockers and labs to monitor?

A

Pt has to be dry and in stable HF (minimal fluid retention)

Don’t start or change dose if pt has exacerbation of HF or fluid overload

• Monitoring: CBC, CMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Why should beta blockers NOT be used as first line for HTN?

A

high risk of developing DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Beta Blockers are contraindicated in…

A
African American pt
asthma/COPD
severe peripheral vascular dx
Raynaud’s
depression 
bradycardia
2nd/3rd defer heart block
hypoglycemic prone
diabetic patient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Patient education for Beta Blockers

A
  • Reports SOB, nocturnal cough, lower extremity edema
  • Don’t stop abruptly
  • Monitor pulse, notify MD < 50
  • w/ diabetic pts: can mask signs of hypoglycemia
  • use caution when performing hazardous task bc of CNS side effects
  • exercised induced fatigue may develop
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Mechanism of Action for Beta blockers

A

MOA → competitive blockade of the B adrenergic receptor
• Results in decrease HR, myocardial contractility, BP and myocardial oxygen
demand
• Suppresses renin release
• Relieve the symptoms of angina by competitively inhibiting sympathetic
stimulation of the heart (so reduced HR and contractility)
• Promote peripheral vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

β1 receptor →

A

mainly in the heart and stimulation from catecholamines causes an
increase in HR, BP, myocardial contractility and AV conduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

β2 receptors →

A

also in heart but mainly in lungs/ peripheral vascular smooth muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Pharmacokinetics of Beta Blockers?

A

• Either excreted by liver or kidney

Propranolol and metoprolol → lipid soluble; almost completely absorbed by the
small intestine and largely metabolized by the liver(These drugs readily enter CNS; SE: lethargy, confusion, sleep disturbances and depression
• Needs to enter the CNS bc it is used to treat migraines
• Have adverse metabolic effects → limits their usefulness in pts w/
hypercholesterolemia and DM (may blunt s/s of hypoglycemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

β-Blockers must be used w/ caution in pts w/ certain heart conditions, such as …

A

heart block,
sinus brady
cardiogenic shock or HF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Βeta blockers can be used to treat:

A

Angina, arrhythmia, compensated HF, post MI, tremors, glaucoma and vascular
HA

the treatment of choice for CHRONIC STABLE and UNSTABLE angina

Most pts will be on nitrates, but β blockers are used when the pt needs to be nitrate
free

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Briefly explain the Renin Angiotensin System (RAS)?

A

drop in blood flow to the renal arteries results in the release of Renin which subsequently activates RAS

Angiotensin is produced in the liver, separated by renin and then converted to Angiotensin I

Angiotensin Converting Enzyme (ACE) converts angiotensin I to Angiotensin II

Angiotensin II is a powerful vasoCONSTRICTOR.
It also stimulates the release of aldosterone, antidiuretic hormone and causes sodium reabsorption of Na+

This leads to Increased fluid retention, higher blood volume, & higher BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What is the MOA of alpha 1 receptor blockers?

A

blocks post synaptic alpha 1 adrenergic receptors resulting in vasodilation and decreased peripheral vascular resistance

tends to affect DIASTOLIC BP more than systolic

also results in relaxation of bladder neck and prostate so often used for the Tx of bladder outlet obstruction such as BPH

examples: doxazosin, prazosin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Describe MOA of centrally acting alpha 2 antagonists

A

stimulate central inhibitory alpha adrenergic receptors

stimulate sympathetic cardioaccelerator and vasoconstrictor areas

results in decreasedsympathetic outflow from the CNS

-reduced peripheral vascular resistance, reduced pressure in the renal system and decreased heart rate

EXAMPLES: clonidine, methyldopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

nonpharmalogical treatment for HTN?

A
lifestyle modification is number 1 recommendation
dietary modification (low sodium)
exercise
stress management
avoid ETOH
smoking cessation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

MOA of direct vasodilators?

A

relaxation of vessel smooth muscle and decreases peripheral vascular resistance

stimulates carotid sinus baroreceptors that can increase HR, renin release and Na+ + H20 retention

EXAMPLE: hydralazine, Minoxidil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

MOA of Renin inhibitors

A

blocks the action of Renin as the RAS cascade begins

EXAMPLE: Tekturna

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

patient monitoring for Methyldopa?

A
  • CBC at baseline
  • LFT’s within 12 weeks of initiating therapy
  • periodic LFT’s
  • Renal function at baseline and periodically
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Patient monitoring for direct vasodilators?

A

consider EKG at baseline

renal function at baseline and periodically

monitor for blood dyscrasias

watch for weight gain and other signs of edema
ANA (check for autoimmune disease)before initiation of Hyrdalazine

56
Q

what type of hypertension is more common in the elderly?

A

systolic

57
Q

What are the dangers with alpha 1 in the lederly?

A

can cause tachycardia and syncope which can be more exaggerated in the elderly

58
Q

which type of HTN med should be used for pts with renal insufficiency?

A

central acting alpha 2 adrenergics

59
Q

What is the risk with clonidine use for the elderly?

A

can cause sedation which can increase risk for falls

60
Q

what OTC meds should be avoided by pts w/ HTN?

A

cold/cough meds –can raise BP

61
Q

What is preload?

A

stretch of the ventricles prior to contraction

preload is created by blood filling the ventricle in preparation for contraction

62
Q

What is afterload?

A

resistance the left ventricle has to overcome to empty its contents into peripheral circulation

63
Q

What is peripheral vascular resistance?

A

pressure (within the periphery) that the left ventricle must overcome w/ each contraction

64
Q

Secondary Risk Factors for high cholesterol

A
  • Diabetes mellitus
  • Cardiovascular disease
  • Thyroid disease
  • Chronic renal disease
  • Chronic obstructive liver disease
  • Certain medications
  • Beta blockers
  • Oral contraceptives
  • Corticosteroids
  • Thiazide diuretics
65
Q

Screening Recommendations for hyperlipidemia

A

Patients age 20 and older every 5 years
• The USPSTF recommends using fasting total cholesterol
and HDL alone in males age 35 and older and females
age 45 and above
• ACC/AHA recommends screening via a non-fasting
triglyceride level. If the level is below 200mg/dl then no
further testing is warranted. If the level is above 200mg/dl,
a fasting lipid panel is warranted

66
Q

Components of a Lipid Panel

A
Total cholesterol (<200mg/dl)
• Triglycerides (<150mg/dl)
• HDL (>60mg/dl)
• LDL (<190mg/dl in non-diabetics and patients without 
CVD)
67
Q

Non-Pharmacologic Therapy for hyperlipidemia

A

In some individuals therapeutic lifestyle changes (TLC)
can result in a 5-15% decrease in LDL
• No more than 200mg of cholesterol per day
• 20-30g of fiber per day
• Total fat intake less than 30% of total calorie intake
• BP control
• 30 minutes of aerobic exercise 5 times per week
• Smoking cessation when applicable
• Healthy weight management

68
Q

what are the Current guidelines target 4 high risk groups that
necessitate statin therapy:

A

Group 1: Patients with known ASCVD
Group 2: Patients with an LDL > 190mg/dl
Group 3: Diabetics aged 40-75 with an LDL of
79-189mg/dl
Group 4: 10 year risk for ASCVD > 7.5% and an
LDL 70-189mg/dl

69
Q

HMG-CoA Reductase Inhibitors (Statins)

• Mechanism of action (MOA)

A

Reversible competitive inhibitors of HMG CoA reductase which is a
rate limiting enzyme used for cholesterol synthesis
• Cholesterol synthesis is reduced thereby reducing intracellular
cholesterol
***Statins may cause a moderate increase in HDL and a mild
decrease in triglycerides

70
Q

• Statin medications are categorized into 3 categories
based upon “strength” or effect at lowering LDL-C

Low intensity(lowers LDL by approx. 30%)

A
  • Simvastatin 10mg
  • Pravastatin 10-20mg
  • Lovastatin 10mg
  • Fluvastatin 20-40mg
  • Pitavastatin 1mg
71
Q
• Statin medications are categorized into 3 categories 
based upon “strength” or effect at lowering LDL-C
Moderate intensity (lowers LDL approx. 30-49%)
A
  • Atorvastatin 10-20mg
  • Rosuvastatin 5-10mg
  • Simvastatin 20-40mg
  • Pravastatin 40-80mg
  • Lovastatin 40mg
  • Fluvastatin XL 80mg
  • Fluvastatin 40mg BID
  • Pitavastatin 2-4mg
72
Q

Statin medications are categorized into 3 categories
based upon “strength” or effect at lowering LDL-C

High intensity (lowers LDL approx. > 50%)

A
  • Atorvastatin 40-80mg

* Rosuvastatin 20-40mg

73
Q

Monitoring parameters for statins

A

Liver function tests (LFTs) at baseline and as clinically
indicated thereafter
• Repeat lipid profile 1-3 months after statin therapy is
initiated
• CK only if clinically indicated i.e. patient reports significant
myalgia

74
Q

Statin Adverse Effects

A
  • Myalgias
  • Increased LFTs
  • Fatigue
  • Headache
  • Insomnia
  • Erectile dysfunction
75
Q

Patient Teaching for Patients

on Statin Therapy

A

• Importance of follow up lab checks
• Importance of immediately reporting myalgias, weakness,
fever
• Importance of taking medication daily
• Importance of therapeutic lifestyle changes in addition to
medication therapy

76
Q

Other Statin Considerations

A

Cholesterol and triglyceride levels increase during
pregnancy
• Statin use is contraindicated during pregnancy and
lactation
• May need dose reduction when prescribed to elderly

77
Q

Other Lipid Lowering Medications

A

Statin therapy is primary treatment for hyperlipidemia
according to ATP IV guidelines

• Fibric acid derivatives
Primarily focused on lowering triglycerides
May increase HDL

• Bile acid sequestrants
Safe treatment because there is no systemic absorption
Exchange anions for bile acids preventing bile acid absorption from
the GI tract

Nicotinic acid
• Increases lipase activity resulting in increased greater triglyceride
removal from plasma

• Selective cholesterol absorption inhibitors
• Inhibits absorption of cholesterol from food intake and internal
sources

78
Q

JNC 7 recs for HTN

A

120-140 (pre HTN)
140-160 (HTN stage 1)
160 + (HTN stage 2)

79
Q

NEW GUIDELINES for HTN

A

120-130 (elevated BP)
130-140 (stage 1)
140 + (stage 2)

80
Q

Main classes of HTN meds

A

A- ACE/ARB (don’t use these together) these increase K+
B – beta BLCOKERS (NOT FIRST LINE)
C -Calcium Channel Blocker (better for AfrAme)
D -Diuretics (better for AF AMER) –LASIX good for low EF

81
Q

Heart Failure is..

A

Heart muscles inability to properly function and move blood into the peripheral circulation
Leads to pulmonary congestion and peripheral volume expansion, subsequently the renin-angiotensin -adolsterone system in activated
s/s SOB, dyspnea on exertion, peripheral edema, fatigue, malaise

82
Q

LOOP DIURETICS are

A

Foundational Tx
START HF pts w/ lood diuretic as soon as Dx
Low dose at first (20-40mg)
Ascending loop of henle to inhibit sodium and potassium reabsorption
Less fluid absorbed back into blood stream= less overall circulating blood volume
EX- Lasix

83
Q

ACE INHIBITORS

A

Produce VASODILATION through the inhibition of the conversion of angiotensin I to angiotensin II
Also inhibit the breakdown of bradykinin which is a powerful vasodilator-more frefloating bradykinin in the syatem
Reduce preload and afterload
ACE inhibitors can cause a dry hacking cough in some pts – result of build-up of bradykinin (best to stop the drug)

84
Q

ARBS (angiotensin receptor blockers)

A

Blocks angiotensisn II receptor s (powerful vasoconstrictor) on surface of target cells
ARBs do not interfere with bradykinin
(s no cough)

85
Q

BETA BLOCKERS

A
Block beta adrenergic receptors
Decreased HR, BP, O2 demand. 
Promotes peripheral vasodilation
Pt needs to be stable in HF and  ‘dry’ (no fluid overload) for use. Esp at initiation or dose changes
Otherwise might worsen pt’s condition
EX-carvedilol, metoprolol
86
Q

SPIRONOLACTONE

A

Add on therapy for HF (usually for pts already on a diuretic) – short term use
Works in the distal renal tubule
Potassium sparing – MUST monitor electrolytes

87
Q

DIGOXIN

A
Inhibits sodium/potassium pump
Increases myocardial contractility
LOG half-life 36 hours
Requires loading dose
NARROW therapeutic window
Frequent lab monitoring required
Pt ed re : digoxin toxicity
88
Q

Pt teaching for HF

A
Understand dosing regimens
Take meds as prescribed
Diet restrictions
Daily weights (3-5 lbs + /week needs to be reported - fluid gain)
Fluid restriction when applicable
89
Q

ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS

A

• (ACEIs) and (ARBs) : similar in their therapeutic uses,, mechanisms of action and adverse effects
• ACEIs and ARBs : commonly used in the treatment of HTN
• They slow the rate of progression of chronic renal failure and diabetic nephropathy
• Mechanism of Action
o 2 types of angiotensin receptors: AT1 and AT 2
o ACEIs inhibit the breakdown of bradykinin (a potent vasodilator) by blocking the enzyme
kininase II (this is thought to cause the classic cough associated w/ taking this)
o ARBs block the effects of angiotensin II by blocking the binding of angiotensin II to its
receptors

90
Q

ARBS differ from ACEIs in 4 ways:

A

▪ (1) ARBs are more active against AT1 receptors that are ACEIs
▪ (2) ACE inhibition is not associated with increased levels of angiotensin II as are
ARBs
▪ (3) ACEIs may increase angiotensin I levels
▪ (4) ACEIs increase levels of bradykinin in contrast to ARBs

91
Q

Treatment Principles for ACE Inhibitors

A

ACEIs generally considered safe and effective in pts with mild to moderate renal
impairment (if renal clearance diminished needs dosage reduction)
o Dehydration and renal insufficiency increase risk of elevated K when ACEI is started
o Advantage of ACEIs/ ARBs: relative lack of serious adverse reactions
o Most common side effect of ACEIs : cough (persistent, dry and hacking)
o ARBs: most serious and potentially life threatening adverse reaction is ANGIOEDEMA
o Pt presents to EC with angioedema – must rule out use of ACEIs
o Other serious adverse effects:
▪ Hyperkalemia, hypotension, acute renal failure
▪ Abrupt withdrawal has NOT resulted in rebound HTN

92
Q

HTN meds for Prevention of Renal Failure in Diabetes

A

o ACEIs and ARBs have been proven to slow the progression of diabetic nephropathy

93
Q

How to Monitor ACE Inhibitors

A

Baseline chemistry, BUN, Cr and UA
o Once dose stable, recheck Cr and K after 2-4 weeks
o Periodic monitor of WBCs for leukopenia
o Monitor supine BP weekly while titrating dose
o ACEIs may cause angioedema… most cases develop within 1 week of starting med ; > 65
yrs, hx of drug rash, seasonal allergies and AA all at high risk of developing angioedema

94
Q

Patient Education for ACe inhibitors

A
ake missed dose ASAP; never take 2 doses together
o Common side effects:
▪ Nonproductive cough
▪ Dizziness
▪ Light headedness
o Serious adverse effects (notify MD)
▪ Swelling (face, mouth, hands, tongue, feet)
▪ Severe itching
▪ fainting
▪ Cloudy urine
▪ Sore throat
▪ Fever
▪ Sudden onset of abdominal pain
▪ Diarrhea/vomiting
95
Q

Signs of excessive K in body:

A
▪ Irregular heartbeat
▪ Leg weakness
▪ Numbness or tingling of hands/ feet
▪ Extreme nervousness
▪ * avoid the use of K containing meds or salt substitutes while receiving this drug
96
Q

fosinopril

A

Food affects rate but not extent of absorption

97
Q

captopril and moexipril

A

Take captopril and moexipril 1 hour before meals

98
Q

Ramipril capsules

A

can be opened and mixed w/ food

99
Q

quinapril

A

Don’t take quinapril w/ high fat meal, reduces absorption by 25%

100
Q

Lisinopril, captopril, enalapril, ramipril

A

decrease dose in renal insufficiency

101
Q

• Lisinopril

A

Neutropenia and agranulocytosis can occur

o Typically takes 2 weeks for BP reduction to occur and 4 weeks for full effects to be seen

102
Q

ACE and ARBS w/ Pregnancy and Lactation

A

Associated w. significant fetal risk
▪ Major congenital malformations – esp CV and CNS noted w/ use of ACEIS during
1st trimester
▪ captopril and enalapril classified by AAP as usually compatible w/ BF and may be
alternatives in certain clinical situations

103
Q

Geriatrics and ACE and ARBs

A

Lower dose for pts w/ renal or hepatic insufficiency

▪ Monitor for volume depletion

104
Q

HTN meds for pts w/ left ventricular

EF < 40% and in those w. HTN, DM or CKD

A

ACE inhibitors should be started and continued indefinitely

105
Q

Don’t give ACE inhibitors to pts w/:

A

ACEI allergy , renal failure, hypotension, shock, hx of bilateral renal artery
stenosis

106
Q

Guidelines o the management of STEMI recommends

A

ACEIs should be initiated

within 24 hours of presentation in pts who are stable

107
Q

How ACEs work Post MI/ High Risk of CV events

A

ACEIs prevent ventricular remodeling and improve endothelial fxn after MI
o Decrease action of fibrin, thereby reducing clotting

108
Q

Calcium Channel Blockers (CCB)

Mechanism of Action

A
  1. Cardiac muscle
    • CCBs decrease the force of myocardial contraction
    • Decreasing the amount of calcium ions causes fewer actin and myosin cross-bridges to be
    formed
    → decreases the force of contraction
    → results in negative inotropic effect
    → decreases cardiac output
  2. Cardiac conduction system
    • CCBs decrease automaticity in the SA node and decrease conduction in the AV node
    • Automaticity: depolarized cell initiates an action potential without an external stimulus
    • Normal characteristic of SA node
    • Depolarization: inward calcium ion current generates an action potential
    • Agents blocking inward calcium ions across SA nodal tissue decrease depolarization and
    suppress automaticity.
    • Agents decreasing calcium ion influx across AV nodal tissue slow AV nodal conduction and AV
    refractory time.
    • When AV conduction is prolonged, rate iv ventricular conduction slows
  3. Vascular smooth muscle
    • CCBs dilate the main coronary arteries and arterioles in normal and ischemic regions
    • Helpful in treatment of angina pectoris
    • CCBs reduce arterial pressure by dilating peripheral arterioles, resulting in reduced BP
    • CCBs effective in treating vasospastic angina
109
Q

How to monitor CCB?

A

Weekly titration
• Monitor periodically (3-6 months) once patient stable.
• Monitor digoxin levels if also taking CCBs
• Kidney and liver function tests

110
Q

Geriatrics and CCBs

A

lower doses to avoid orthostatic hypotension; CCBs often drug of choice for elderly

111
Q

Pregnancy/lactation and CCBs

A

Category C, excreted in breast milk (Nifedipine, verapamil, and diltiazem)

112
Q

Race and CCBs

A

More effective in African-Americans

113
Q

Nifedepine

• Indication:

A

vasospastic angina, stable angina, Raynaud’s disease, hypertension
o No effect on cardiac conduction => do not cause/treat arrythmias

114
Q

Nifedepine Mode of action:

A

dilator of vascular smooth muscle, mild negative inotropic effect (less than
verapamil)

115
Q

Nifedepine

A

Onset of action: 20 min
• Half-life: 2-5 hours
• Duration: 4-8 hours
• Excretion: renal (80%)
• Precautions: acute hepatic injury (elevated LFTs), peripheral edema
• Side effects: Pedal edema, cough, dyspnea, nausea, headache, flushing, dizziness

116
Q
  1. Verapamil
A

• Indication: stable angina, vasospastic angina, hypertension.
• Mode of action: dilator of smooth muscle – less potent than nifedipine significant negative
inotropic effect, relieves coronary spasms
• Onset of action:
• Half-life:
• Duration:
• Excretion: renal and feces
• Precaution: hypotension, may cause first degree block, elevated liver enzymes, antiplatelet
effect
• Side effects: constipation, muscle cramps, Stevens-Johnson syndrome

117
Q
  1. Diltiazem
A

Indication: stable angina, vasospastic angina, hypertension, Raynaud’s disease.
• Mode of action: more effect on cardiac muscle than vascular smooth muscle
• Onset of action: 30 min
• Half-life: 3-7 hours
• Duration:
• Excretion: renal and bile
• Precaution: aortic stenosis, bradycardia, breastfeeding, hepatic disease, ventricular dysfunction.
• Side effects: pedal edema, headache, Stevens-Johnson syndrome

118
Q

pt education for CCBs

A

• May experience hypotensive effects during titration
• Report swelling of feet or shortness of breath, irregular heartbeats, nausea, dizziness,
constipation
• Extended-release tablets may appear as inert shells in feces
• Avoid grapefruit juice
• Abrupt withdrawal of CCBs may cause increased chest pain => gradually taper dose

119
Q

Angina classification

A

Stable or chronic - no change in past 2 months in terms of frequency, duration (<15 min), or
causes. Symptom pattern is reproducible.
• Unstable – change in pattern of pain (frequency, severity, duration), less precipitating factors.
Pts should be admitted to coronary care unit.
• Variant (Prinzmetal’s angina) - coronary artery spasm. Very rare. Pain occurs at rest and
develops b/c of spasm and not result of increased myocardial O2 demand
• Silent ischemia – asymptomatic episodes of myocardial ischemia that can be detected with ECG

120
Q

Stable or chronic angina

A

no change in past 2 months in terms of frequency, duration (<15 min), or
causes. Symptom pattern is reproducible.

121
Q

unstable angina

A

change in pattern of pain (frequency, severity, duration), less precipitating factors.
Pts should be admitted to coronary care unit.

122
Q

Variant (Prinzmetal’s angina)

A

coronary artery spasm. Very rare. Pain occurs at rest and

develops b/c of spasm and not result of increased myocardial O2 demand

123
Q

Silent ischemia

A

asymptomatic episodes of myocardial ischemia that can be detected with ECG

124
Q

treatment of Stable angina (long-term mgmt):

A
antiplatelets, β-blockers, CCBs, long-acting nitrates, potassium
channel openers (ranolazine), ACEI, aspirin, statin, possible revascularization
125
Q

treatment of Unstable angina

A

aspirin, clopidogrel/ticlopidine

126
Q

treatment of Acute attack of angina

A

nitrates

127
Q

Acute Attack of angina

A

Remember MONA (minus the morphine and not in that order)
• Give NTG sublingually at 3-5 min intervals for 3 doses. If angina is worse or unimproved 5 min
after 1st dose, call EMS.
• Give O2, at 2L/min, via nasal cannula.
• Chew regular aspirin (325 mg) while waiting for EMS.
• Thrombolytic therapy

128
Q

Nitrates

• Mode of action:

A

Relax vascular smooth muscle via stimulation of intracellular cyclic guanosine
monophosphate production
o Reduce myocardial O2 demand, by decreasing preload and (to a lesser extent) afterload
o Major dilation of venous bed
o Increase use of coronary collaterals so perfusion to myocardium is improved

129
Q

Drug interactions: for nitrates

A

Alcohol. (NTG + ETOH can lower BP)

130
Q

Precautions w/ nitrates

A

Older pts at risk for syncope with NTG
o Tolerance to nitrates is an issue. To prevent tolerance, interrupt therapy for 8-12
hours/day (take off patch or stop oral medication in PM and restart in AM)

131
Q

Side effects w/ nitrates

A

flushing of face, brief throbbing headache, increased HR, dizziness, light-headed
when change position rapidly

132
Q

teaching for nitrates

A

Have pts keep record of PRN medication use, bring to appts
o Keep record of anginal attacks, frequency, NTG side effects
o Have pt sit or lie down before take NTG
o Obtain new Rx every 3 months and discard old NTG. (NTG loses its strength 3 months
after opening the bottle.)
o Store NTG in original dark glass container w/o cotton wadding and out of sunlight.
o Rest for 10-15 min after pain is relieved
o Notify provider if you have blurring of vision, persistent headache, or dry mouth
o Use NTG in prevention of possible anginal attacks (exercise, sex)
o Don’t stop taking NTG abruptly

133
Q

Cardinal Points of Treatment for HTN meds

A

Loop diuretics for fluid retention
• ACE inhibitor (ACEI) unless contraindicated / or ARB if ACEI not tolerated
• Β-blocker – esp. For diastolic HF (start only when pt is stable on ACEI)
• Digoxin for systolic HF and a-fib
• Spironolactone if above are not effective
• Nitrates and hydralazine in African-Americans only, if cannot tolerate above
• CCB only if needed for angina or HTN, and if EF is preserved
• Na+ restriction
Digoxin

134
Q

Digoxin uses

A

• Indication: Used for systolic HF b/c of its inotropic properties, a-fib, diuretic failure
• Mode of action:
o Inhibits Na+/K+ pump
o Increases myocardial contractility
o Decreases HR
• Onset of action: Requires loading dose, 5-6 days to reach steady state
• Duration: Very long half-life: 36 hours
• Excretion: excreted unchanged, so levels can quickly reach toxic proportions. Excreted over 6
days d/t long half-life

135
Q

HMG – CoA Reductase Inhibitors (Statins)

MOA

A

decreases cholesterol synthesis causing a decrease in LDL. Also increases HDL.

136
Q

HMG – CoA Reductase Inhibitors (Statins)

monitoring

A

Ask pt about myalgias; check CPK if present
• Eye exam for cataract risk
• LFTs at baseline and as clinically indicated thereafter
• Lipid panel at baseline and 1-3 months after therapy initiation
• Protease inhibitors and statins taken together may raise the blood levels of statins and
increase the risk of muscle injury

137
Q

Atorvastatin (Liptor) Contraindications

A
  • Contraindications:
  • Active liver disease
  • Pregnancy/lactation
  • Precautions:
  • Liver dysfucnction
  • Rhabdo with acute renal failure
  • Peak Concentration– 1-2 hr
  • Half Life– 14hr